DC CFAR Clinical and Population Sciences (CPS) Core Co-Director, Dr. Manya Magnus (GW) and colleagues from the HIV Prevention Trials Network (HPTN) published an article in Oxford Academic in January 2020 entitled "Cabotegravir Is Not Associated With Weight Gain in Human Immunodeficiency Virus-uninfected Individuals in HPTN 077".
The HPTN clinical research site is a collaboration with the GW MFA. Key DC CFAR collaborators on the study include Drs. Marc Siegel (GW), Irene Kuo (GW) and Jeanne Jordan (GW).
The study evaluated weight changes and metabolic parameters among participants in the HIV Prevention Trials Network Study 077 (HPTN 077) that are using Cabotegravir. Cabotegravir is an integrase inhibitor in development for HIV prevention and as part of ART for treatment.